CLBIO Corline Biomedical AB (publ)
Corline Biomedical AB (publ) develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB (publ) was incorporated in 1991 and is based in Uppsala, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Corline Biomedical (STO: CLBIO)
›
Corline Biomedical (STO: CLBIO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 14.35 SEK on 19 November 2026, down 25.3% over 52 weeks. Its 52-week range is 9.800 SEK to 19.95 SEK: the price is 28.1% below the high and 46.4% above the low.
Its market capitalisation is 375.01M SEK.
Corline Biomedical reports return on equity of -15.7%, an operating margin of -103.6% and revenue up 82.9% year over year.
It holds more cash than debt, a net cash position of 29.87M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 20.00 SEK is 39.4% above the current price.